Mode
Text Size
Log in / Sign up
N/A N=134 Randomized Single-blind Treatment

Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities

Anxiety

Enrolled (actual)
134
Serious AEs
0.0%
Results posted
May 2019
Primary outcome: Primary: Penn State Worry Questionnaire - A (PSWQ-A) at 6 Months — 26.73; 26.25; 22.04; 23.04 units on a scale — p=0.77

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Cognitive behavior treatment (Behavioral); Information and referral (Behavioral)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Baylor College of Medicine
Primary completion
Sep 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Penn State Worry Questionnaire - A (PSWQ-A) at 6 Months
26.73; 26.25; 22.04; 23.04 0.77
PRIMARY
Penn State Worry Questionnaire - A (PSWQ-A) at 9 Months
26.73; 26.25; 21.87; 20.18 0.07
PRIMARY
Generalized Anxiety Disorder-7 (GAD-7) at 6 Months
11.00; 10.56; 7.13; 8.11 0.34
PRIMARY
Generalized Anxiety Disorder-7 (GAD-7) at 9 Months
11.00; 10.56; 7.54; 6.62 0.08
SECONDARY
Geriatric Anxiety Inventory - SF (GAI-SF) at 6 Months
3.39; 3.30; 2.25; 2.48 0.45
SECONDARY
Geriatric Anxiety Inventory - SF (GAI-SF) at 9 Months
3.39; 3.30; 2.65; 2.31 0.13
SECONDARY
Patient Health Questionnaire Depression Scale (PHQ 8) at 6 Months
11.41; 11.13; 7.28; 8.48 0.52
SECONDARY
Patient Health Questionnaire Depression Scale (PHQ 8) at 9 Months
11.41; 11.13; 7.39; 7.00 0.29
SECONDARY
Geriatric Depression Scale Short Form (GDS) at 6 Months
5.97; 5.61; 3.75; 4.33 0.14
SECONDARY
Geriatric Depression Scale Short Form (GDS) at 9 Months
5.97; 5.61; 3.80; 3.92 0.59
SECONDARY
Insomnia Severity Index (ISI) at 6 Months
13.44; 13.00; 10.08; 10.13 0.64
SECONDARY
Insomnia Severity Index (ISI) at 9 Months
13.44; 13.00; 9.81; 9.51 0.35
SECONDARY
Late-Life Function and Disability Instrument (LL-FDI) Disability Subscale - Frequency at 6 Months
48.90; 48.05; 51.05; 49.83 0.52
SECONDARY
Late-Life Function and Disability Instrument (LL-FDI) Disability Subscale - Frequency at 9 Months
48.90; 48.05; 50.85; 49.64 0.92
SECONDARY
Late-Life Function and Disability Instrument (LL-FDI) Disability Subscale - Limitation at 6 Months
59.05; 59.39; 64.54; 62.64 0.59
SECONDARY
Late-Life Function and Disability Instrument (LL-FDI) Disability Subscale - Limitation
59.05; 59.39; 62.30; 62.45 0.89
SECONDARY
Medical Outcomes Study 12-Item Short-Form Health Survey Physical Component Summary (SF-12 PCS) at 6 Months
38.38; 38.51; 37.86; 36.45 0.64
SECONDARY
Medical Outcomes Study 12-Item Short-Form Health Survey Physical Component Summary (SF-12 PCS)
38.38; 38.51; 38.37; 36.93 0.94
SECONDARY
Medical Outcomes Study 12-Item Short-Form Survey Mental Component Summary (SF-12 MCS) at 6 Months
40.08; 40.14; 47.25; 45.91 0.98
SECONDARY
Medical Outcomes Study 12-Item Short-Form Survey Mental Component Summary (SF-12 MCS) at 9 Months
40.08; 40.14; 46.98; 47.27 0.88
SECONDARY
PTSD Checklist-5 (PCL-5) Total at 6 Months
28.77; 18.02; 26.92; 20.35 0.31
SECONDARY
PTSD Checklist-5 (PCL-5) Total at 9 Months
28.77; 26.92; 18.28; 18.53 0.96
SECONDARY
Health Service Use at 6 Months
64; 56; 47; 45 0.52
SECONDARY
Health Service Use at 9 Months
64; 56; 52; 39 0.04 sig
SECONDARY
Hospital Admissions at 6 Months
12; 10; 12; 5 0.04 sig
SECONDARY
Hospital Admissions at 9 Months
12; 10; 14; 3 0.001 sig
SECONDARY
Social Service or Resource Use at 6 Months
22; 17; 17; 11 0.42
SECONDARY
Social Service or Resource Use at 9 Months
22; 17; 18; 14 0.85
SECONDARY
Psychological Service Use at 6 Months
42; 29; 31; 31 0.55
SECONDARY
Psychological Service Use at 9 Months
42; 29; 26; 20 0.54

Summary

The purpose of this research study is to see how helpful two different interventions offered through the Calmer Life program are in reducing worry and improving mood. The investigators also want to understand how a program like Calmer Life can be offered in underserved communities.

Eligibility Criteria

Inclusion Criteria

  • PSWQ greater than 22

Exclusion Criteria

  • PHQ score less than 20
  • Active suicidal intent
  • Active psychosis or bipolar disorder
  • Substance abuse
  • Cognitive impairment
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02391363). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search